Last reviewed · How we verify
LY3023703
At a glance
| Generic name | LY3023703 |
|---|---|
| Also known as | LY3023703 phosphate |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal (PHASE2)
- A Multiple Dose Study of LY3023703 in Healthy Participants (PHASE1)
- A Study of [14C]-LY3023703 in Healthy Participants (PHASE1)
- A Single Dose Study of LY3023703 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3023703 CI brief — competitive landscape report
- LY3023703 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI